Evaluation of specific antigen and prostatic acid phosphatase specificity. Study of false values.
We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1305 subjects without malignant prostatic pathology by double antibody RIA I125 to evaluate their specificity. When we set a second upper normal limit of 10 ng/ml for PSA and 2.5 ng/ml for PAP there was a significant increase of specificity. There were 2 and 3.7% false positive results in non-prostatic benign pathologies, 1.8 and 7.9% in non-prostatic malignant, 3.5 and 4.7% in non-complicated benign prostatic hypertrophy (BPH) and 3.3% for both in chronic prostatitis. In patients with complicated BPH and acute prostatitis the results were 64.8 and 24% for PSA and 20 and 16% for PAP. In conclusion, PSA is more specific than PAP in patients without acute inflammatory pathology of the prostate; the high rate of false positive values in the latter excludes its usefulness in these patients as diagnostic tumoral markers.
D000135:Acid Phosphatase / Q000097:blood*; D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D005189:False Positive Reactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000201:enzymology* / Q000276:immunology; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D012737:Sex Factors
D014408:Biomarkers, Tumor; D000135:Acid Phosphatase